Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 39
1.
PLoS One ; 16(11): e0258727, 2021.
Article En | MEDLINE | ID: mdl-34735494

INTRODUCTION: Patients with hemoglobinopathies have been reported to have higher rates of pulmonary complications. Few studies have investigated the association between thalassemia and asthma in children. METHODS: We used the data of one million individuals randomly selected from the Registry for Beneficiaries of the National Health Insurance Research Database. One thalassemic child was matched with four control children without thalassemia according to sex, birth year, birth season, prematurity, and previous enteroviral infection. RESULTS: A total of 800 hundred thalassemic children and 3200 controls were included. Children with thalassemia had higher rates of developing asthma (41.81 vs 25.70 per 1000 person-years, P < 0.001) than the non-thalassemia controls with an adjusted hazard ratio of 1.37 (95% confidence interval [CI] = 1.19-1.58). Boys in the thalassemia cohort had a significantly higher adjusted incidence hazard ratio (IRR) of asthma than those in the non-thalassemia cohort (adjusted IRR = 1.45, 95% CI = 1.02-1.73). The risk of atopic and nonatopic asthma was higher in the thalassemia cohort than in the non-thalassemia cohort (IRR = 1.3, 1.61, respectively). CONCLUSIONS: Children with thalassemia were more likely to develop asthma. More attention should be paid to the early diagnosis of asthma and prevention of asthma attacks.


Asthma/epidemiology , Enterovirus Infections/epidemiology , Respiratory Tract Infections/epidemiology , Thalassemia/epidemiology , Adolescent , Adult , Asthma/complications , Asthma/pathology , Asthma/virology , Child , Child, Preschool , Cohort Studies , Databases, Factual , Enterovirus Infections/complications , Enterovirus Infections/pathology , Enterovirus Infections/virology , Female , Humans , Infant , Male , Men , Premature Birth , Proportional Hazards Models , Respiratory Tract Infections/pathology , Respiratory Tract Infections/virology , Risk Factors , Thalassemia/complications , Thalassemia/pathology , Thalassemia/virology , Young Adult
2.
Hemoglobin ; 45(3): 175-179, 2021 May.
Article En | MEDLINE | ID: mdl-34121572

Serum ferritin is an acute phase protein; importantly, its level is noticeably increased in response to iron overload and systemic inflammation. The iron overload status in thalassemia patients has been recognized as a potential way to measure liver iron concentration (LIC) levels using magnetic resonance imaging (MRI). The aim of this study was to investigate the effect of chronic viral hepatitis on the level of serum ferritin in patients with thalassemia. A cross-sectional study was conducted involving chronic viral hepatitis infection. Mean serum ferritin and LIC levels were recorded. The LIC values were used to divide the patients into two groups; a higher LIC group (>5 mg Fe/g) and a lower LIC group (<5 mg Fe/g). Mean serum ferritin levels were then compared between the two LIC groups. We identified 32 thalassemia patients comprising of 13 chronic viral hepatitis patients, seven patients with hepatitis B virus (HBV), and six patients with hepatitis C virus (HCV). With regard to the group with higher LIC values, the mean serum ferritin levels in the hepatitis group were significantly higher than for those in the non hepatitis group (1776 ± 488 vs. 967 ± 860 ng/mL, p = 0.03). Furthermore, the linear correlation between the mean serum ferritin levels and the viral load in the non transfusion-dependent thalassemia (NTDT) group were found to be significantly correlated (r = 0.7, p = 0.04). Chronic viral hepatitis was determined to be a possible casualty of disproportionately high ferritin levels in the NTDT group.


Ferritins/blood , Hepatitis C , Iron Overload , Thalassemia , Cross-Sectional Studies , Hepatitis C/blood , Humans , Iron Overload/etiology , Liver , Thalassemia/complications , Thalassemia/virology
3.
Am J Trop Med Hyg ; 104(4): 1569-1576, 2021 02 01.
Article En | MEDLINE | ID: mdl-33534738

There are an estimated 2,000 children with ß-thalassemia in the province Baluchistan of Pakistan. These children are at high risk of acquiring transfusion-transmitted infections (TTIs) due to their need of regular blood transfusions for survival. Therefore, we investigated the frequencies of TTIs among these multi-transfused patients in a region where the WHO guidelines for blood safety are not always followed. Sera from 400 children (mean age 7.7 ± 4.70 years) treated at two thalassemia centers in Baluchistan were investigated for TTIs. Eleven (2.8%) were hepatitis B surface antigen positive, and 72 (18.3%) had anti-hepatitis C virus (HCV), two of which were infected with both viruses. Only 22% of the children had been reached by the program for universal hepatitis B virus (HBV) vaccination which started in 2004. Half (51%) of the HCV infected had also been HBV infected. The HBV- and HCV-infected patients were older and had received more blood transfusions than the uninfected patients (P < 0.001). Molecular characterization of the viral strains revealed the presence of several genetically different strains in at least three HBV- and seven HCV-infected children. This is the first study to demonstrate infections with multiple HBV or HCV strains simultaneously infecting thalassemia patients. These may become the source for new emerging recombinant viruses of unknown virulence. The high prevalence of anti-HCV-positive children, and the presence of HBV infections among children who should have been vaccinated, highlights an urgent need for improvements of blood safety in this region of Pakistan.


Hepatitis B/epidemiology , Hepatitis C/epidemiology , Thalassemia/epidemiology , Thalassemia/virology , Transfusion Reaction/epidemiology , Transfusion Reaction/virology , Adolescent , Adult , Blood Safety/standards , Child , Child, Preschool , Female , Hepacivirus/pathogenicity , Hepatitis B/etiology , Hepatitis B virus/pathogenicity , Hepatitis C/etiology , Humans , Male , Pakistan/epidemiology , Prevalence , Young Adult
4.
Arch Virol ; 165(10): 2193-2203, 2020 Oct.
Article En | MEDLINE | ID: mdl-32638116

Patients with thalassemia major are at high risk of hepatitis C through blood transfusion from donors infected by hepatitis C virus (HCV). The use of direct-acting antiviral (DAA) therapy against such HCV infections has increased in different populations. However, resistant viral variants can affect treatment outcomes, and therefore improved surveillance strategies are needed. Accordingly, we aimed to evaluate resistance-associated substitutions (RASs) to HCV DAAs at the baseline of treatment in thalassemia patients in a referral center. Out of 89 thalassemia patients who suffered from HCV infection and were referred to our center between 2016 and 2017, 43 underwent further analysis of the HCV nonstructural proteins NS5A and NS5B using polymerase chain reaction (PCR) sequencing methods. Unique primers were designed using bioinformatics software for separate detection of HCV subtypes 1a, 3a, and 1b. Detection of RASs was performed based on previously published literature. Statistical analysis was carried out using SPSS version 19. The participants, 60.4% (26/43) of whom were male, had a mean age ± standard deviation (SD) of 33.0 ± 5.0 years. HCV subtype 1a was found in 27 cases, 3a in 13, and 1b in three. In HCV subtype 1a there were 163 mutations in NS5A and 212 mutations in NS5B. The frequency of RASs was 20.9% (8 RASs in 9 patients), including M28V and H58P in subtype 1a, L28M, R30Q, C316N, and C316S in subtype 1b, and S24F in subtype 3a. Statistically, the subtype 1b and a higher mutation rate in NS5A were associated with RASs (p-value < 0.05). The emergence of natural RASs to HCV DAAs serves as a warning of the risk of drug resistance in response to the broad usage of antivirals. However, relapses in these DAA-treated HCV-infected thalassemia patients are rarely reported. Our findings indicate that the prevalence of RASs prevalence at baseline was 20.9% in these patients, and this calls for extrapolation to a larger population study, as highlighted in other studies, with larger sample sizes, high-throughput methods, and follow-up in order to fully evaluate treatment outcomes in RASs-detected individuals. Optimized therapeutic strategies, particularly in complex, difficult-to-cure patients, can effectively prevent DAA treatment failure as a result of selection for RASs.


Antiviral Agents/therapeutic use , Drug Resistance, Viral/drug effects , Hepacivirus/drug effects , Hepatitis C, Chronic/drug therapy , Thalassemia/virology , Adult , Drug Resistance, Viral/genetics , Female , Genotype , Hepacivirus/genetics , Humans , Male , Mutation/genetics , Referral and Consultation , Viral Nonstructural Proteins/genetics
5.
Cytokine ; 106: 148-153, 2018 06.
Article En | MEDLINE | ID: mdl-29196132

BACKGROUND: Multitransfused thalassemic individuals are at high risk of developing transfusion transmitted Hepatitis C virus (HCV) infection. The aim of the study was to correlate the effects of host cytokine single nucleotide polymorphisms of TNF-α (-308 A/G) and IFN-γ (+874 A/T) in spontaneous or IFN induced treatment response in the HCV infected thalassemic individuals. METHODS: A total of 427 HCV sero-reactive thalassemic individuals were processed for HCV viral genomic diversity and host gene polymorphisms analysis of TNF-α (-308 A/G) and IFN-γ (+874 A/T). RESULTS: Out of 427 HCV sero-reactive individuals, 69.09% were found to be HCV RNA positive with genotype 3 as the predominant infecting strain (94.29%). Study highlighted that, A allele was significantly associated with (p < .05) spontaneous clearance of HCV infection and G allele was correlated with viral persistence at TNF-α (-308) gene polymorphism. Whereas in case of IFN-γ (+874) SNPs, A allele was significantly responsible (p < .05) for spontaneous clearance than T allele. Our study also indicated that in relapsed cases, IFN-γ (+874) T allele is more responsible than A allele. Though no significant correlation was found at both TNF-α (-308) and IFN-γ (+874) gene polymorphism among SVR and relapsed thalassemic patients. CONCLUSION: A allele at both TNF-α (-308) and IFN-γ (+874) were strongly associated with spontaneous clearance among this population. But in case of SVR and relapsed cases no significant association was found. This cytokine gene polymorphisms pattern will help clinicians to take an informed decision about therapeutic management of HCV infected thalassemic individuals.


Blood Transfusion , Genetic Association Studies , Hepacivirus/physiology , Hepatitis C/genetics , Interferon-gamma/genetics , Polymorphism, Single Nucleotide/genetics , Thalassemia/genetics , Tumor Necrosis Factor-alpha/genetics , Adolescent , Adult , Child , Child, Preschool , Female , Genotype , Hepacivirus/genetics , Hepatitis C/blood , Hepatitis C/drug therapy , Humans , Interferon-alpha/therapeutic use , Male , RNA, Viral/genetics , Thalassemia/virology , Young Adult
6.
Intervirology ; 60(3): 102-108, 2017.
Article En | MEDLINE | ID: mdl-28972950

OBJECTIVE: Torque teno virus (TTV) is a ubiquitous virus that is commonly associated with blood transfusion. The main aims of this study were to evaluate the incidence of TTV in polytransfused children with thalassemia and to determine for the first time the prevalent TTV genotypes in Egypt. METHODS: TTV was detected in 2 groups by nested PCR: the first group comprised 200 children with thalassemia, and the second included age- and sex-matched healthy children with no history of blood transfusion. RESULTS: TTV was detected in 60 and 57%, respectively, of the children with thalassemia and the healthy children. Among the TTV-positive children with thalassemia, 71.6% were HCV positive. No hepatitis B surface antigen was detected in the thalassemic children. Significant elevations of alanine transaminase and aspartate transaminase were found in TTV-positive patients with thalassemia compared to TTV-negative patients. Phylogenetic analysis of sequenced TTV isolates showed close relationships to genotypes 1 and 2. CONCLUSION: TTV is highly prevalent among children with thalassemia in Egypt, with a relatively high infection rate also detected among healthy children.


DNA Virus Infections/virology , Thalassemia/virology , Torque teno virus/genetics , Blood Transfusion , Child , Female , Genotype , Humans , Male , Phylogeny , Sequence Analysis, DNA , Torque teno virus/isolation & purification
7.
Transfusion ; 57(6): 1376-1384, 2017 06.
Article En | MEDLINE | ID: mdl-28419488

BACKGROUND: Hepatitis C virus (HCV) is the major posttransfusion infection in multitransfused individuals in India with thalassemia major. To our knowledge, this study is the first conducted to correlate and comprehend the effects of the host interleukin (IL)28B gene polymorphism at loci rs12979860 and rs8099917 in spontaneous or interferon (IFN)-induced treatment response in the HCV-seroreactive individuals with thalassemia major. STUDY DESIGN AND METHODS: A total of 557 HCV-seroreactive individuals with thalassemia were processed for HCV viral genotyping and host IL28B single-nucleotide polymorphism analysis at loci rs12979860 and rs8099917. RESULTS: Of 557 individuals, 70.92% were found to be HCV RNA positive with Genotype 3 (95.18%) as predominant strain. A favorable CC allele at locus rs2979860 and TT allele at rs8099917 were 75.31 and 77.16%, respectively, which was strongly associated with spontaneous clearance of infection (p < 0.05). Of 85 IFN-treated cases, 56 achieved sustained virologic response (SVR) whereas 27 were relapsed cases. Among these patients who achieved SVR, a favorable CC/TT allele at rs12979860/rs8099917 was found to be predominant with 76.79 and 66.07%, respectively, whereas in the case of relapsed patients, unfavorable CT (55.56%) and TG (59.26%) alleles were found to be predominant. Additionally, low serum ferritin level was significantly associated with SVR. CONCLUSION: CC at rs12979860 and TT at rs8099917 was strongly associated with spontaneous clearance and SVR in the population with thalassemia. Low age group and low serum ferritin level are important cofactors. This allelic pattern will aid clinicians in making an informed decision about prognosis and therapeutic management.


Blood Transfusion , Hepatitis C, Chronic/pathology , Hepatitis C, Chronic/virology , Interleukins/genetics , Polymorphism, Single Nucleotide/genetics , Thalassemia/genetics , Thalassemia/therapy , Adolescent , Alleles , Child , Child, Preschool , Female , Ferritins/blood , Genotype , Hepacivirus/pathogenicity , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/genetics , Humans , Interferons , Male , Thalassemia/blood , Thalassemia/virology , Treatment Outcome
8.
Cancer ; 123(5): 751-758, 2017 03 01.
Article En | MEDLINE | ID: mdl-27911488

The incidence of hepatocellular carcinoma (HCC) in patients with thalassemia is on the rise. The 2 well recognized HCC risk factors in thalassemia are iron overload and chronic viral infection with hepatitis C. The carcinogenicity of iron is related to its induction of oxidative damage, which results in genotoxicity, and to immunologic dysregulation, which attenuates cancer immune surveillance. Chronic hepatitis B and C infections lead to necroinflammation, which can prompt progression to HCC, but an independent role of hepatitis B virus in hepatic carcinogenesis among patients with thalassemia has not been demonstrated. Screening patients who have thalassemia using magnetic resonance imaging-based liver iron concentration measurement and liver ultrasound is recommended for early detection of iron overload and HCC, respectively. Prevention primarily resides in hepatitis B vaccination, donor blood screening, hepatitis treatment, and iron chelation. Although solid data is lacking on the outcomes of HCC treatment in patients with thalassemia, a personalized approach tailored to the individual patient's comorbidities remains necessary for treatment success. Treatment modalities for HCC include surgical resection, chemoembolization, and liver transplantation, among others. Multicenter studies are needed to better explore therapeutic targets that can improve the prognosis of these patients. Cancer 2017;123:751-58. © 2016 American Cancer Society.


Carcinoma, Hepatocellular/physiopathology , Liver Neoplasms/physiopathology , Thalassemia/physiopathology , Carcinogenesis/genetics , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/diagnostic imaging , Hepacivirus/pathogenicity , Hepatitis B, Chronic/diagnostic imaging , Hepatitis B, Chronic/pathology , Hepatitis B, Chronic/virology , Hepatitis C, Chronic/diagnostic imaging , Hepatitis C, Chronic/pathology , Hepatitis C, Chronic/virology , Humans , Iron Overload/diagnostic imaging , Iron Overload/physiopathology , Liver Neoplasms/complications , Liver Neoplasms/diagnostic imaging , Risk Factors , Thalassemia/complications , Thalassemia/virology
10.
J Trop Pediatr ; 59(4): 309-13, 2013 Aug.
Article En | MEDLINE | ID: mdl-23542535

OBJECTIVE: Detecting the current prevalence of hepatitis C virus (HCV) among Egyptian multitransfused thalassemic patients and evaluating the risk of its transmission within their family members. METHODS: Multitransfused Egyptian thalassemia patients (n = 137) were tested for HCV infection. Household contacts of positive members were compared with household contacts of HCV-negative patients. Antibodies to HCV were detected by enzyme immunoassay. Antibody-positive cases were retested for viral load using reverse transcriptase polymerase chain reaction. HCV genotyping was performed on positive samples of the patients and the positive household contacts. RESULTS: In all, 34.4% of patients (n = 47) were positive for HCV antibodies and RNA. The study of 24 families of HCV-positive patients showed 14 affected family members (19.2%). In 27 families of HCV-negative patients, four family members were affected (4.9%). HCV genotyping of seven families was similar in both patients and their family members. CONCLUSION: Our results support the role of intrafamilial transmission in the spread of HCV.


Family , Hepacivirus/isolation & purification , Hepatitis C Antibodies/analysis , Hepatitis C/transmission , Thalassemia/therapy , Transfusion Reaction , Adolescent , Adult , Child , Contact Tracing , Egypt/epidemiology , Enzyme-Linked Immunosorbent Assay , Family Health , Female , Genotype , Hepacivirus/genetics , Hepatitis C/epidemiology , Hepatitis C/genetics , Hepatitis C/virology , Humans , Middle Aged , Prevalence , RNA, Viral/analysis , RNA, Viral/genetics , Reverse Transcriptase Polymerase Chain Reaction , Risk Factors , Thalassemia/epidemiology , Thalassemia/virology , Viral Load , Young Adult
12.
FEMS Immunol Med Microbiol ; 62(3): 247-62, 2011 Aug.
Article En | MEDLINE | ID: mdl-21585562

Human parvovirus B19 (B19V) is a small (22-24 nm) nonenveloped DNA virus belonging to the genus Erythrovirus (family Parvoviridae). Although it generally causes self-limiting conditions in healthy people, B19V infection may have a different outcome in patients with inherited hemolytic anemias. In such high-risk individuals, the high-titer replication may result in bone marrow suppression, triggering a life-threatening drop of hemoglobin values (profound anemia, aplastic crisis). To date there is no consensus concerning a B19V screening program either for the blood donations used in the hemotherapy or for high-risk patients. Moreover, questions such as the molecular mechanisms by which B19V produces latency and persistent replication, the primary site (sites) of B19V infection and B19V immunopathology are far from being known. This review summarizes general aspects of B19V molecular characteristics, pathogenesis and diagnostic approaches with a focus on the role of this pathogen in blood transfusions and in patients with some hemoglobinopathies (sickle-cell disease, thalassemia).


Anemia, Sickle Cell/virology , Blood Transfusion , Parvoviridae Infections/blood , Parvovirus B19, Human , Thalassemia/virology , Blood Donors , Humans
13.
Blood Cells Mol Dis ; 45(3): 215-8, 2010 Oct 15.
Article En | MEDLINE | ID: mdl-20605573

Patients with transfusion-dependent thalassemia major often develop liver fibrosis due to liver iron overload and/or hepatitis virus C (HCV) infection. Hyaluronic acid (HA) plays a prominent role in the pathogenesis of liver fibrosis and the elevation of serum HA concentration is due to either increased synthesis by inflammatory cells and hepatic stellate cells or impaired degradation by sinusoidal endothelial cells (SECs) and thus is proposed as a non-invasive biomarker of liver fibrosis either by itself and/or included in the Hepascore formula. In this study we evaluated prospectively a screening of liver fibrosis in 201 adult patients aged 19-54 years with transfusion-dependent thalassemia major, based on HA measurements. 41/201 patients were HCV-RNA (+). HA was measured with a turbidimetric assay applied on a clinical chemistry analyzer. The Hepascore was computed from the results by using the model previously published. The main results of the study showed that: a) HA levels were increased in 110/201 (55%) thalassemia patients 85.0 ± 10.3 ng/ml, ranged from 15.0 to 1495.0 µg/l, compared to 20.8 ± 7.4 µg/l reference laboratory values, p<0.001, b) HA levels were significantly higher in HCV-RNA(+) compared to HCV-RNA(-) patients, 171.6 ± 202 vs 53.8 ± 35.5 µg/l, p<0.0001 c) no significant correlations were found between HA levels and/or Hepascore with ferritin and liver iron content (LIC) assessed with MRI (p>0.324 and p>0.270, respectively). Our findings indicate that hyaluronic acid measurements contribute to the assessment of liver fibrosis in patients with thalassemia and might be helpful for further evaluation of patients with liver biopsy if this is truly needed. Furthermore, liver fibrosis in thalassemia seems to be independent from liver siderosis.


Hyaluronic Acid/metabolism , Liver Cirrhosis/metabolism , Liver/metabolism , Thalassemia/metabolism , Adult , Evaluation Studies as Topic , Female , Ferritins/metabolism , Hepacivirus , Hepatitis C/blood , Hepatitis C/pathology , Humans , Iron/metabolism , Liver/pathology , Liver/virology , Liver Cirrhosis/complications , Liver Cirrhosis/pathology , Liver Cirrhosis/virology , Male , Middle Aged , Prospective Studies , RNA, Viral/blood , Siderosis/metabolism , Siderosis/pathology , Thalassemia/complications , Thalassemia/pathology , Thalassemia/virology
16.
Pak J Biol Sci ; 11(13): 1738-41, 2008 Jul 01.
Article En | MEDLINE | ID: mdl-18819629

This research was aimed to investigate the prevalence and clinical impact of occult HBV infection in thalassemic patients with chronic HCV infection. In this cross-sectional study we have totally examined 60 patients suffering HBV and HCV infections by PCR and RT-PCR methods, respectively, in Kerman province of Iran. ELISA technique (RADIM, Italy) was used to detect anti-HBc, anti-HBs and HBsAg. The serum level of liver enzymes (SGOT, SGPT, DB, TB and ALK) were analyzed in the HCV infected patients (MAN, IRAN). Statistical analyses performed using t-test and Chi-square. We found that 27 cases (out of 60) were infected by HCV but HBV-DNA was not seen in HCV infected patients. Present findings also showed that none of samples were HBsAg positive but 9 (33%) (out of 27) HCV-RNA positive patients were anti-HBc positive and 11 (40.7%) were positive for anti-HBs. We found that SGOT, SGPT, DB, TB and ALK are above normal in 27 (100%), 19(70.3%), 12(44.5%), 15 (55.5%) and 15 (55.5%) RNA-HCV positive patients, respectively. The prevalence of hepatitis C infection is very high in thalassemic patients and based on other studies our results showed that the prevalence of HCV infection in Kerman is more than other provinces of Iran. In contrast with other studies HBV-DNA in these patients could not be detected, hence, it seems that occult HBV infection isn't frequent in Iranian thalassemic patients who suffering from chronic HCV infection.


DNA, Viral/analysis , Hepatitis B virus/genetics , Hepatitis C/complications , Hepatitis C/virology , Thalassemia/complications , Thalassemia/virology , DNA, Viral/genetics , Female , Follow-Up Studies , Hepatitis B virus/isolation & purification , Hepatitis C/enzymology , Humans , Iran , Liver/enzymology , Male , Thalassemia/enzymology , Time Factors
17.
Asian Pac J Allergy Immunol ; 25(2-3): 169-74, 2007.
Article En | MEDLINE | ID: mdl-18035805

Human parvovirus B19 infection was studied in 60 thalassemic patients in Thailand. Seroprevalence, persistence of parvovirus B19 and their genotypes were identified in blood samples. Prevalence of anti-parvovirus B19 IgG and DNA found in thalassemic patients were 38% and 13%, respectively. Anti-parvovirus B19 IgM could be detected in 4% of these positive anti-parvovirus B19 IgG patients. The seroprevalence and parvovirus B19 DNA in patients with a history of blood transfusion were not significantly higher than those without such a history (44% vs. 34% and 20% vs. 9%, respectively). Phylogenetic analysis of NS1 nucleotide sequences of three parvovirus B19 samples revealed that they were parvovirus B19 genotype 1. They showed low genetic diversity from prototype (Au) strain. We concluded that acute and chronic persistent parvovirus B19 infection were found in the thalassemic Thai patients. Chronic persistence of parvovirus B19 infection might play important clinical role in thalassemic patients because of the high prevalence of parvovirus B19 DNA. Blood transfusion had no significant influence to increase the prevalence of parvovirus B19 infection in thalassemic patients.


Antibodies, Viral/blood , Parvoviridae Infections/complications , Parvovirus B19, Human/immunology , Thalassemia/complications , Adolescent , Adult , Base Sequence , DNA, Viral/blood , Female , Genotype , Humans , Male , Middle Aged , Molecular Sequence Data , Parvoviridae Infections/epidemiology , Parvoviridae Infections/immunology , Parvoviridae Infections/virology , Parvovirus B19, Human/genetics , Parvovirus B19, Human/isolation & purification , Phylogeny , Seroepidemiologic Studies , Thailand/epidemiology , Thalassemia/immunology , Thalassemia/virology
19.
Int J STD AIDS ; 17(8): 543-6, 2006 Aug.
Article En | MEDLINE | ID: mdl-16925902

Although screening for human T-cell lymphotropic virus types I and II (HTLV-I/II) antibodies in volunteer blood donors has been systematic in Greece since 1995, the epidemiology and the determinants of HTLV-I/II infection are not well defined among population groups. During 1997-2005, the prevalence of HTLV-I/II infection was investigated in a sample of 2016 pregnant women, 102 multitransfused haematologic and oncologic patients, 93 thalassaemic patients and 57 intravenous drug users originating from four geographic areas of Pelopennese peninsula, Greece. One recipient of HTLV-I infected blood and the relatives of a woman died from adult T-cell leukaemia/lymphoma (ATTL) related to HTLV-I have also been tested. The subjects were initially screened by an enzyme immunoassay whereas Western blot, INNO-LIA HTLV, polymerase chain reaction and nucleotide sequencing confirmed the infection. One thalassaemic patient had proved HTLV-I infection giving an overall prevalence of 11 per 1000. In the recipient of the infected blood and in two of the five relatives of the woman died from ATTL, HTLV-I infection was also detected. In none of the pregnant women, multitransfused patients and intravenous drug users HTLV-I/II infection was confirmed. These data suggest that HTLV-I is present in Greece among populations at high-risk. However, they would not support the need for HTLV-I/II antenatal screening in Greece.


Human T-lymphotropic virus 1 , Human T-lymphotropic virus 2 , Leukemia, T-Cell/epidemiology , Leukemia-Lymphoma, Adult T-Cell/epidemiology , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/virology , Blotting, Western/methods , Female , Greece/epidemiology , Humans , Immunoenzyme Techniques/methods , Polymerase Chain Reaction/methods , Pregnancy , Prevalence , Prospective Studies , Risk Factors , Substance Abuse, Intravenous , Thalassemia/virology
20.
Hemoglobin ; 30(1): 119-24, 2006.
Article En | MEDLINE | ID: mdl-16540424

Hepatocellular carcinoma (HCC) is a complication of cirrhosis. Due to blood transfusions, patients with beta-thalassemia (thal) are often infected with either hepatitis C virus (HCV) or hepatitis B virus (HBV). In the past, many patients did not survive long enough to develop HCC. The recent improvements in prognosis have helped in the diagnosis of HCC that has developed. The aim of this study was to evaluate HCC incidence in beta-thal. We performed liver ultrasound (US) on all adults without a previous diagnosis of HCC. Risk factors (iron overload, HCV infection, HBV infection, cirrhosis) were evaluated. One hundred and eight thalassemia patients have been evaluated; of whom three were excluded (two patients as they were under the age of 18 years and one patient because he had a previous history of HCC). Seventy-two patients [31 had thalassemia major (TM), 41 had thalassemia intermedia (TI)] with risk factors (iron overload in 72, HCV infection in 46, HBV infection in two, cirrhosis in 10) and 33 (four with TM and 29 with TI) without risk factors underwent liver US. Overall, two patients were found to have a newly developed HCC. Of these two patients, one was treated with surgery and the other with percutaneous radiofrequency. Further follow-up did not show any evidence of recurrence after 23 and 15 months, respectively. Ultrasound screening can allow early detection and treatment of HCC in thalassemia patients.


Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/epidemiology , Liver Neoplasms/diagnosis , Liver Neoplasms/epidemiology , Thalassemia/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/virology , Child , Comorbidity , Disease Progression , Female , Follow-Up Studies , Hepatitis B/blood , Hepatitis B/epidemiology , Hepatitis C/blood , Hepatitis C/epidemiology , Humans , Incidence , Italy/epidemiology , Liver/diagnostic imaging , Liver Neoplasms/virology , Male , Middle Aged , Prospective Studies , Risk Factors , Sensitivity and Specificity , Thalassemia/diagnosis , Thalassemia/virology , Ultrasonography
...